Spinal Cord InjuriesDISCUSNCT04936620
Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling
A study testing Duroplasty and Spinal surgery in people with Spinal Cord Injuries, run by St George's, University of London at 34 sites in 12 countries.
Trial summary
QUESTION. Does duroplasty improve outcome after spinal cord injury? WHAT DO WE STUDY? We will investigate whether performing a surgical procedure called duroplasty improves outcomes after spinal cord injury. Read more about this study
- Who is it for?
- Ages 16 years and older
- Conditions the study is for
- Spinal Cord Injuries
- What is being tested?
- Duroplasty and Spinal surgery
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 222 participants
- Where
- 34 sitesin 12 countries
- Study dates
- 8 Oct 2021to 30 Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Age ≥16 years
- Severe cervical (C2 - T1) traumatic spinal cord injury (AIS grade A-C)
- Deemed to require and be suitable for surgery that includes laminectomy by local surgeon
- Surgery within 72 hours of traumatic spinal cord injury
- Able to provide informed consent or consultee declaration or proxy consent.
Who cannot join
- Dural tear due to traumatic spinal cord injury
- Life-limiting or rehabilitation-restricting co-morbidities
- Thoracic or lumbar traumatic spinal cord injury
- Other central nervous system disease
Trial locations and contacts
34 sites in 12 countries. Contact the study team or a site near you to ask about taking part.
Ghazal Ebrat contact
34 sites in 12 countries
United Kingdom18 sites, 13 recruiting
- Active, not recruiting
National Spinal Injuries Centre
Aylesbury
- Recruiting
Queen Elizabeth Hospital Birmingham
Birmingham
Vladimir Petrik
- Recruiting
Addenbrooke's Hospital
Cambridge
Ivan Timofeev
- Recruiting
Royal Infirmary of Edinburgh
Edinburgh
Andreas Demetriades
- Recruiting
Queen Elizabeth University Hospital
Glasgow
Likhith Alakandy
- Recruiting
Hull Royal Infirmary
Hull
Vasileios Arzoglou
- Recruiting
Leeds General Infirmary
Leeds
Christopher Derham
- Recruiting
The Walton Centre
Liverpool
Martin Wilby
- Recruiting
St George's Hospital
London
Marios C Papadopoulos, MD, 02087254179, mpapadop@sgul.ac.uk
Marios Papadopoulos
- Recruiting
St Mary's Hospital
London
Haider Kareem
- Active, not recruiting
The London Spinal Cord Injury Centre
London
- Recruiting
The Royal London Hospital
London
Christopher Uff
- Recruiting
Queen's Medical Centre
Nottingham
Daniel D'Aquino
- Active, not recruiting
Midlands Centre for Spinal Injuries,
Oswestry
- Recruiting
Salford Royal
Salford
Shrijit Panikkar
- Recruiting
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield
Marcel Ivanov
Rohit Bhide
- Active, not recruiting
North West Regional Spinal Injuries Centre
Southport
- Active, not recruiting
Pinderfields Hospital
Wakefield
Austria4 sites, 4 recruiting
- Recruiting
Universität Klinik für Neurochirurgie
Innsbruck
Claudius Thome
- Recruiting
Kepler University Hospital
Linz
Wolfgang Senker
- Recruiting
University Hospital Salzburg
Salzburg
Lukas Grassner
- Recruiting
St Polten University Hospital
Sankt Pölten
Franz Marhold, 43 2742/9004-12961, neurochirurgie@stpoelten.lknoe.at
Germany2 sites, 2 recruiting
- Recruiting
BG Unfallklinik Frankfurt am Main
Frankfurt
Jonathan Neuhoff
- Recruiting
Klinik und Poliklinik für Neurochirurgie Universitätsklinikum Frankfurt, 60596 FRANKFURT AM MAIN
Frankfurt
Marcus CZABANKA, Prof Dr Med, 0049 (0) 69 6301 5295, czabanka@med.uni-frankfurt.de
Marcus CZABANKA, Prof dr Med, czabanka@med.uni-frankfurt.de
Israel2 sites, 2 recruiting
- Recruiting
Hadassah Medical Center
Jerusalem
Guy Rosenthal
- Recruiting
Shaare Zedek Medical Centre
Jerusalem
Cezar Mizrahi
China1 site, 1 recruiting
- Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei
Xiaodong Guo, 027 85726646, xiaodongguo@hust.edu.cn
Peiran Xue, xuepeiran@outlook.com
Czechia1 site, 1 recruiting
- Recruiting
Masaryk Hospital
Ústí nad Labem
Aleš Hejčl, 420477112884, ales.hejcl@kzcr.eu
Denmark1 site, 1 recruiting
- Recruiting
Aarhus University Hospital
Aarhus
Mikkel Mylius Rasmussen
Finland1 site, 1 recruiting
- Recruiting
Kuopio University Hospital
Kuopio
Nils Danner, 358400911568, Nils.Danner@pshyvinvointialue.fi
Slovenia1 site, 1 recruiting
- Recruiting
University Medical Centre Ljubljana
Ljubljana
Marko Jug
Spain1 site, 1 recruiting
- Recruiting
12 de Octubre University Hospital
Madrid
Igor Paredes
Sweden1 site, 1 recruiting
- Recruiting
Skåne University Hospital
Lund
Niklas Marklund
About this study
QUESTION. Does duroplasty improve outcome after spinal cord injury?
WHAT DO WE STUDY? We will investigate whether performing a surgical procedure called duroplasty improves outcomes after spinal cord injury.
Read more
WHY SPINAL CORD INJURY? Spinal cord injury is a devastating condition that causes permanent disability such as paralysis, numbness and loss of bladder and bowel control. Currently, there are no treatments shown to improve outcome after spinal cord injury.
WHAT IS DUROPLASTY? Duroplasty is an operation that involves opening the tough membrane around the cord, called the dura, and stitching a patch of artificial dura to expand the space around the swollen cord.
WHY IS DUROPLASTY BEING STUDIED? Based on our preliminary evidence, we think that the dura causes cord pressure after injury. We have shown in a small study of patients that performing this operation safely and effectively reduces pressure on the injured cord.
WHO IS ELIGIBLE? Adult patients with severe spinal cord injuries in the neck who will have surgery within 72 hours.
WHAT TREATMENT? Those who agree to take part will be allocated by chance (like tossing a coin) to standard treatment or standard treatment plus duroplasty. Some patients will also be asked to take part in a smaller study that involves placing probes at the injury site.
WHERE? Initially, we will recruit patients from U.K. Major Trauma Centres. Most assessments will be done in U.K. Spinal Injury Centres. Later on, we we also started recruiting from overseas.
HOW LONG? We aim to recruit 222 - 260 patients over 4 years. Patients will be followed up for a year.
WHAT DO WE ASSESS? Patients will be assessed (using questionnaires and by examination) how well they can use their hands, walk, control their bladder and bowel and their quality of life. Some of these assessments will be repeated at 3, 6 and 12 months after surgery.
WHAT IS THE OPTIONAL MECHANISTIC STUDY? DISCUS includes an optional study for at least 50 patients who will take part in the randomised controlled trial. The aim of the mechanistic study is to determine how duroplasty improves outcome, i.e. whether duroplasty reduces cord compression, improves blood flow to the injured cord perfusion, improves cord metabolism and reduces cord inflammation.
WHAT IS THE OPTIONAL INFORMATION STUDY? For the first two years, a study called QuinteT Recruitment Intervention (QRI) is designed to optimise patient recruitment and informed consent in the trauma setting.
Read the detailed description
RESEARCH QUESTION: After severe traumatic spinal cord injury (TSCI), does the addition of dural decompression to bony decompression (includes laminectomy) improve muscle strength in the limbs at 6 months, compared with bony decompression alone? BACKGROUND: TSCI is a devastating condition that affects about 1,000 people in the UK annually. Most remain disabled, tetraplegic or wheelchair bound and are dependent on carers with significant cost to patients, carers and the NHS. Surgery aims to reduce spinal deformity, stabilise the spine and achieve bony decompression of the cord. To date, no treatments have been shown to improve outcome.
AIMS / OBJECTIVES: The primary aim is to determine if, in patients with acute, severe TSCI, the addition of dural decompression to bony decompression improves muscle strength. We hypothesise that, after TSCI, the cord swells and is compressed against the dura. Secondary objectives are to assess patient impact i.e. functional outcomes, health related quality of life (HRQoL), complication rates and mortality. Mechanistic sub-studies aim to determine if the addition of duroplasty improves cord perfusion, reduces cord ischaemia and cord inflammation.
METHODS: This is a prospective, phase III, multicentre randomised controlled trial (RCT). We aim to recruit 222 adults with acute, severe cervical TSCI (American spinal injuries association Impairment Scale (AIS) grade A, B or C) who will be randomised 1:1 to undergo bony decompression alone versus bony decompression with duroplasty. Patients and assessors will be blinded to study arm. The primary outcome is change in AIS motor score (AMS) at 6 months compared with admission (Delta-AMS); secondary outcomes will assess function (grasp, walking, urinary + anal sphincters), HRQoL, complications, need for further surgery and mortality, assessed at baseline, 3 months, 6 months and 12 months from randomisation. A subgroup of 50 patients (25 per arm) will also have observational monitoring from the injury site using a pressure probe (intraspinal pressure ISP, spinal cord perfusion pressure SCPP) and microdialysis (MD) catheter (cord metabolism: tissue glucose, lactate, pyruvate, lactate-to-pyruvate ratio (LPR), glutamate, glycerol); cord inflammation: tissue chemokines/cytokines. Initially, patients were only recruited from UK major trauma centres (MTCs). DISCUS is now also recruiting patients from International sites.
TIMELINES FOR DELIVERY: The initial study duration was 72 months and includes 6 months set-up, 48 months recruitment, 12 months to complete follow-up and 6 months for data analysis and final reporting of results. There will be a formal stop/go review at month 15 (after 9 months of recruitment) to ensure a minimum of 4 sites have been opened and 8 patients randomised. If these targets are met, the trial will recruit for a further 36 months. Data from the pilot will be included in the final analysis. Recruitment has been extended to end on 30 June 2027.
ANTICIPATED IMPACT AND DISSEMINATION: It is anticipated that the addition of duroplasty to standard of care will improve muscle strength in patients; this has obvious benefits for patients and their carers as well as substantial gains for the NHS and society including economic implications. If this RCT shows that the addition of duroplasty to standard treatment is beneficial, it is anticipated that duroplasty will become standard NHS care in all 26 UK MTCs, and internationally. Participants will be informed of study findings via the Surgical Intervention Trials Unit (SITU) website and the Spinal Injuries Association (SIA).
- Conditions
- Spinal Cord Injuries
- Being tested
- Duroplasty, Spinal surgery
- Keywords
- Decompression, surgical; Neurosurgery; Paralysis
- Medical subject headings
- Spinal Cord Injuries, Paralysis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DuroplastyProcedure or surgery
Expansion Duroplasty
Spinal surgeryProcedure or surgery
Spinal surgery including laminectomy
| Study group | Role | What they receive |
|---|---|---|
| Duroplasty | Active comparator | Duroplasty (includes Surgery with Laminectomy) Receives: Procedure: Duroplasty; Procedure: Spinal surgery |
| No duroplasty | Active comparator | No duroplasty (but includes surgery with Laminectomy) Receives: Procedure: Spinal surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in AIS motor score
Change in American Spinal Injury Association Impairment Scale total limb motor score at 6 months
Measured: 6 months versus baseline
Secondary outcomes (14)
Change in AIS light touch score
Change in American Spinal Injury Association Impairment Scale total light touch sensory score
Measured: 6 months versus baseline
Change in AIS pin prick score
Change in American Spinal Injury Association Impairment Scale total pin prick sensory score
Measured: 6 months versus baseline
Change in AIS grade
Change in American Spinal Injury Association grade
Measured: 6 months versus baseline
CUE-Q
Capabilities of upper extremity-questionnaire (CUE-Q)
Measured: 6 months
Grip strength
Hand grip strength assessed with dynamometer
Measured: 6 months
WISCI II
Walking Index for Spinal Cord Injury version ii
Measured: 6 months
SCIM III
Spinal Cord Independence Measure version III
Measured: 6 months
SF-36
Short Form survey 36
Measured: 6 months, 12 months
Spinal re-operations
Number of reoperations on spine
Measured: 12 months
Adverse events
Procedure Specific complications and adverse events
Measured: 12 months
Mortality
Mortality
Measured: 12 months
Length of hospital stay
Length of hospital stay
Measured: 12 months
MRI
Magnetic resonance imaging of cervical spine
Measured: 2 weeks, 6 months
Injury site physiology and metabolism (optional)
Optional mechanistic study: Mean daily intraspinal pressure, spinal cord perfusion pressure, tissue glucose, lactate, pyruvate, glycerol, glutamate, cytokines measured from the injury site
Measured: Up to 5 days after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jun 2021
- Study start8 Oct 2021
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Spinal Cord InjuriesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Phase III clinical trial: randomised, controlled, double blind, multi-centre, superiority \+ Optional mechanistic study
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 222 participants (estimated)
Sponsor and investigators
- Lead sponsor
- St George's, University of London
- Sponsor type
- University, hospital or other
- Collaborators
- St George's University Hospitals NHS Foundation Trust, St. Mary's University, Twickenham, University of Bristol, Ohio State University, University of Cambridge, University of Oxford, Buckinghamshire Healthcare NHS Trust, Paracelsus Medical University
- Responsible party
- Sponsor
- Investigators
- Marios C Papadopoulos, Principal investigator, St George's, University of London, U.K.Samira Saadoun, Principal investigator, St George's, University of London, U.K.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04936620
- Sponsor's protocol ID
- 2021.0056
- Other IDs
- 25573423
- Acronym
- DISCUS
- Status last verified
- Jul 2026
- First submitted
- 21 Jun 2021
- Last updated
- 6 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Appropriately anonymised datasets from our sponsored research will be made available for further analysis wherever possible under our Research Data Management policy: https://www.sgul.ac.uk/about/governance/policies/research-data-management
Publications
Saadoun S, Asif H, Papadopoulos MC. The concepts of Intra Spinal Pressure (ISP), Intra Thecal Pressure (ITP), and Spinal Cord Perfusion Pressure (SCPP) in acute, severe traumatic spinal cord injury: Narrative review. Brain Spine. 2024 Oct 16;4:103919. doi: 10.1016/j.bas.2024.103919. eCollection 2024.
PubMed 39654909Saadoun S, Grassner L, Belci M, Cook J, Knight R, Davies L, Asif H, Visagan R, Gallagher MJ, Thome C, Hutchinson PJ, Zoumprouli A, Wade J, Farrar N, Papadopoulos MC. Duroplasty for injured cervical spinal cord with uncontrolled swelling: protocol of the DISCUS randomized controlled trial. Trials. 2023 Aug 7;24(1):497. doi: 10.1186/s13063-023-07454-2.
PubMed 37550727Werndle MC, Saadoun S, Phang I, Czosnyka M, Varsos GV, Czosnyka ZH, Smielewski P, Jamous A, Bell BA, Zoumprouli A, Papadopoulos MC. Monitoring of spinal cord perfusion pressure in acute spinal cord injury: initial findings of the injured spinal cord pressure evaluation study*. Crit Care Med. 2014 Mar;42(3):646-55. doi: 10.1097/CCM.0000000000000028.
PubMed 24231762Phang I, Werndle MC, Saadoun S, Varsos G, Czosnyka M, Zoumprouli A, Papadopoulos MC. Expansion duroplasty improves intraspinal pressure, spinal cord perfusion pressure, and vascular pressure reactivity index in patients with traumatic spinal cord injury: injured spinal cord pressure evaluation study. J Neurotrauma. 2015 Jun 15;32(12):865-74. doi: 10.1089/neu.2014.3668. Epub 2015 May 4.
PubMed 25705999Phang I, Zoumprouli A, Papadopoulos MC, Saadoun S. Microdialysis to Optimize Cord Perfusion and Drug Delivery in Spinal Cord Injury. Ann Neurol. 2016 Oct;80(4):522-31. doi: 10.1002/ana.24750. Epub 2016 Aug 19.
PubMed 27463064Saadoun S, Papadopoulos MC. Acute, Severe Traumatic Spinal Cord Injury: Monitoring from the Injury Site and Expansion Duraplasty. Neurosurg Clin N Am. 2021 Jul;32(3):365-376. doi: 10.1016/j.nec.2021.03.008. Epub 2021 May 7.
PubMed 34053724Asif H, Tsan SEH, Boseta E, Zoumprouli A, Papadopoulos MC, Saadoun S. Effect of Sevoflurane Concentration, Blood Pressure, Arterial Carbon Dioxide Tension, Temperature, and Stimulation on Spinal Cord Blood Flow in Patients Undergoing Spinal Surgery: An Exploratory Study. Anesthesiology. 2026 Apr 1;144(4):1012-1015. doi: 10.1097/ALN.0000000000005911. Epub 2026 Jan 30. No abstract available.
PubMed 41619740
Study at a glance
From the registry record, last updated by the sponsor on 6 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Duroplasty for Injured Cervical Spinal Cord With Uncontrolled Swelling
- ClinicalTrials.gov ID
- NCT04936620
- Acronym / sponsor ID
- DISCUS / 2021.0056
- Conditions
- Spinal Cord Injuries
- Keywords
- Decompression, surgical; Neurosurgery; Paralysis
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 222 participants (estimated)
- Lead sponsor
- St George's, University of LondonUniversity, hospital or other
- Collaborators
- St George's University Hospitals NHS Foundation Trust, St. Mary's University, Twickenham, University of Bristol, Ohio State University, University of Cambridge, University of Oxford, Buckinghamshire Healthcare NHS Trust, Paracelsus Medical University
- Study start
- 8 Oct 2021 (actual)
- Primary completion
- 30 Jun 2028 (estimated)
- Study completion
- 30 Jun 2028 (estimated)
- First posted
- 23 Jun 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
QUESTION. Does duroplasty improve outcome after spinal cord injury?
WHAT DO WE STUDY? We will investigate whether performing a surgical procedure called duroplasty improves outcomes after spinal cord injury.
WHY SPINAL CORD INJURY? Spinal cord injury is a devastating condition that causes permanent disability such as paralysis, numbness and loss of bladder and bowel control. Currently, there are no treatments shown to improve outcome after spinal cord injury.
WHAT IS DUROPLASTY? Duroplasty is an operation that involves opening the tough membrane around the cord, called the dura, and stitching a patch of artificial dura to expand the space around the swollen cord.
WHY IS DUROPLASTY BEING STUDIED? Based on our preliminary evidence, we think that the dura causes cord pressure after injury. We have shown in a small study of patients that performing this operation safely and effectively reduces pressure on the injured cord.
WHO IS ELIGIBLE? Adult patients with severe spinal cord injuries in the neck who will have surgery within 72 hours.
WHAT TREATMENT? Those who agree to take part will be allocated by chance (like tossing a coin) to standard treatment or standard treatment plus duroplasty. Some patients will also be asked to take part in a smaller study that involves placing probes at the injury site.
WHERE? Initially, we will recruit patients from U.K. Major Trauma Centres. Most assessments will be done in U.K. Spinal Injury Centres. Later on, we we also started recruiting from overseas.
HOW LONG? We aim to recruit 222 - 260 patients over 4 years. Patients will be followed up for a year.
WHAT DO WE ASSESS? Patients will be assessed (using questionnaires and by examination) how well they can use their hands, walk, control their bladder and bowel and their quality of life. Some of these assessments will be repeated at 3, 6 and 12 months after surgery.
WHAT IS THE OPTIONAL MECHANISTIC STUDY? DISCUS includes an optional study for at least 50 patients who will take part in the randomised controlled trial. The aim of the mechanistic study is to determine how duroplasty improves outcome, i.e. whether duroplasty reduces cord compression, improves blood flow to the injured cord perfusion, improves cord metabolism and reduces cord inflammation.
WHAT IS THE OPTIONAL INFORMATION STUDY? For the first two years, a study called QuinteT Recruitment Intervention (QRI) is designed to optimise patient recruitment and informed consent in the trauma setting.
Detailed description
RESEARCH QUESTION: After severe traumatic spinal cord injury (TSCI), does the addition of dural decompression to bony decompression (includes laminectomy) improve muscle strength in the limbs at 6 months, compared with bony decompression alone? BACKGROUND: TSCI is a devastating condition that affects about 1,000 people in the UK annually. Most remain disabled, tetraplegic or wheelchair bound and are dependent on carers with significant cost to patients, carers and the NHS. Surgery aims to reduce spinal deformity, stabilise the spine and achieve bony decompression of the cord. To date, no treatments have been shown to improve outcome.
AIMS / OBJECTIVES: The primary aim is to determine if, in patients with acute, severe TSCI, the addition of dural decompression to bony decompression improves muscle strength. We hypothesise that, after TSCI, the cord swells and is compressed against the dura. Secondary objectives are to assess patient impact i.e. functional outcomes, health related quality of life (HRQoL), complication rates and mortality. Mechanistic sub-studies aim to determine if the addition of duroplasty improves cord perfusion, reduces cord ischaemia and cord inflammation.
METHODS: This is a prospective, phase III, multicentre randomised controlled trial (RCT). We aim to recruit 222 adults with acute, severe cervical TSCI (American spinal injuries association Impairment Scale (AIS) grade A, B or C) who will be randomised 1:1 to undergo bony decompression alone versus bony decompression with duroplasty. Patients and assessors will be blinded to study arm. The primary outcome is change in AIS motor score (AMS) at 6 months compared with admission (Delta-AMS); secondary outcomes will assess function (grasp, walking, urinary + anal sphincters), HRQoL, complications, need for further surgery and mortality, assessed at baseline, 3 months, 6 months and 12 months from randomisation. A subgroup of 50 patients (25 per arm) will also have observational monitoring from the injury site using a pressure probe (intraspinal pressure ISP, spinal cord perfusion pressure SCPP) and microdialysis (MD) catheter (cord metabolism: tissue glucose, lactate, pyruvate, lactate-to-pyruvate ratio (LPR), glutamate, glycerol); cord inflammation: tissue chemokines/cytokines. Initially, patients were only recruited from UK major trauma centres (MTCs). DISCUS is now also recruiting patients from International sites.
TIMELINES FOR DELIVERY: The initial study duration was 72 months and includes 6 months set-up, 48 months recruitment, 12 months to complete follow-up and 6 months for data analysis and final reporting of results. There will be a formal stop/go review at month 15 (after 9 months of recruitment) to ensure a minimum of 4 sites have been opened and 8 patients randomised. If these targets are met, the trial will recruit for a further 36 months. Data from the pilot will be included in the final analysis. Recruitment has been extended to end on 30 June 2027.
ANTICIPATED IMPACT AND DISSEMINATION: It is anticipated that the addition of duroplasty to standard of care will improve muscle strength in patients; this has obvious benefits for patients and their carers as well as substantial gains for the NHS and society including economic implications. If this RCT shows that the addition of duroplasty to standard treatment is beneficial, it is anticipated that duroplasty will become standard NHS care in all 26 UK MTCs, and internationally. Participants will be informed of study findings via the Surgical Intervention Trials Unit (SITU) website and the Spinal Injuries Association (SIA).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- Phase III clinical trial: randomised, controlled, double blind, multi-centre, superiority + Optional mechanistic study
| Arm | Type | Receives |
|---|---|---|
| Duroplasty | Active comparator | Procedure: Duroplasty, Procedure: Spinal surgeryDuroplasty (includes Surgery with Laminectomy) |
| No duroplasty | Active comparator | Procedure: Spinal surgeryNo duroplasty (but includes surgery with Laminectomy) |
Who may qualify
- Ages
- 16 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Age ≥16 years
- Severe cervical (C2 - T1) traumatic spinal cord injury (AIS grade A-C)
- Deemed to require and be suitable for surgery that includes laminectomy by local surgeon
- Surgery within 72 hours of traumatic spinal cord injury
- Able to provide informed consent or consultee declaration or proxy consent.
Key exclusion criteria (4 listed)
- Dural tear due to traumatic spinal cord injury
- Life-limiting or rehabilitation-restricting co-morbidities
- Thoracic or lumbar traumatic spinal cord injury
- Other central nervous system disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DuroplastyExpansion Duroplasty | Procedure or surgery | Duroplasty |
| Spinal surgerySpinal surgery including laminectomy | Procedure or surgery | Duroplasty, No duroplasty |
Primary outcome
Change in AIS motor score
Time frame: 6 months versus baseline
Change in American Spinal Injury Association Impairment Scale total limb motor score at 6 months
14 secondary outcomes
Change in AIS light touch score
Time frame: 6 months versus baseline
Change in AIS pin prick score
Time frame: 6 months versus baseline
Change in AIS grade
Time frame: 6 months versus baseline
CUE-Q
Time frame: 6 months
Grip strength
Time frame: 6 months
WISCI II
Time frame: 6 months
SCIM III
Time frame: 6 months
SF-36
Time frame: 6 months, 12 months
Spinal re-operations
Time frame: 12 months
Adverse events
Time frame: 12 months
Mortality
Time frame: 12 months
Length of hospital stay
Time frame: 12 months
MRI
Time frame: 2 weeks, 6 months
Injury site physiology and metabolism (optional)
Time frame: Up to 5 days after surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Jul 2026.
- Background: PubMed 39654909Saadoun S, Asif H, Papadopoulos MC. The concepts of Intra Spinal Pressure (ISP), Intra Thecal Pressure (ITP), and Spinal Cord Perfusion Pressure (SCPP) in acute, severe traumatic spinal cord injury: Narrative review. Brain Spine. 2024 Oct 16;4:103919. doi: 10.1016/j.bas.2024.103919. eCollection 2024.
- Background: PubMed 37550727Saadoun S, Grassner L, Belci M, Cook J, Knight R, Davies L, Asif H, Visagan R, Gallagher MJ, Thome C, Hutchinson PJ, Zoumprouli A, Wade J, Farrar N, Papadopoulos MC. Duroplasty for injured cervical spinal cord with uncontrolled swelling: protocol of the DISCUS randomized controlled trial. Trials. 2023 Aug 7;24(1):497. doi: 10.1186/s13063-023-07454-2.
- Background: PubMed 24231762Werndle MC, Saadoun S, Phang I, Czosnyka M, Varsos GV, Czosnyka ZH, Smielewski P, Jamous A, Bell BA, Zoumprouli A, Papadopoulos MC. Monitoring of spinal cord perfusion pressure in acute spinal cord injury: initial findings of the injured spinal cord pressure evaluation study*. Crit Care Med. 2014 Mar;42(3):646-55. doi: 10.1097/CCM.0000000000000028.
- Background: PubMed 25705999Phang I, Werndle MC, Saadoun S, Varsos G, Czosnyka M, Zoumprouli A, Papadopoulos MC. Expansion duroplasty improves intraspinal pressure, spinal cord perfusion pressure, and vascular pressure reactivity index in patients with traumatic spinal cord injury: injured spinal cord pressure evaluation study. J Neurotrauma. 2015 Jun 15;32(12):865-74. doi: 10.1089/neu.2014.3668. Epub 2015 May 4.
- Background: PubMed 27463064Phang I, Zoumprouli A, Papadopoulos MC, Saadoun S. Microdialysis to Optimize Cord Perfusion and Drug Delivery in Spinal Cord Injury. Ann Neurol. 2016 Oct;80(4):522-31. doi: 10.1002/ana.24750. Epub 2016 Aug 19.
- Background: PubMed 34053724Saadoun S, Papadopoulos MC. Acute, Severe Traumatic Spinal Cord Injury: Monitoring from the Injury Site and Expansion Duraplasty. Neurosurg Clin N Am. 2021 Jul;32(3):365-376. doi: 10.1016/j.nec.2021.03.008. Epub 2021 May 7.
- Derived from this study: PubMed 41619740Asif H, Tsan SEH, Boseta E, Zoumprouli A, Papadopoulos MC, Saadoun S. Effect of Sevoflurane Concentration, Blood Pressure, Arterial Carbon Dioxide Tension, Temperature, and Stimulation on Spinal Cord Blood Flow in Patients Undergoing Spinal Surgery: An Exploratory Study. Anesthesiology. 2026 Apr 1;144(4):1012-1015. doi: 10.1097/ALN.0000000000005911. Epub 2026 Jan 30. No abstract available.
- DISCUS NIHR Research AwardLink provided by the sponsor.
- DISCUS ISRCTN registryLink provided by the sponsor.
- DISCUS websiteLink provided by the sponsor.
- Wings for LifeLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Appropriately anonymised datasets from our sponsored research will be made available for further analysis wherever possible under our Research Data Management policy: https://www.sgul.ac.uk/about/governance/policies/research-data-management
Related trials for Spinal Cord Injuries
Recruiting
MyHand-SCI: An Active Hand Orthosis for Spinal Cord Injury
Spinal Cord Injuries, Tetraplegia
Recruiting
Clinical Outcome Assessment for AT & BCI
Spinal Cord Injury, ALS (Amyotrophic Lateral Sclerosis)
Recruiting
Transcutaneous Spinal Cord Stimulation Combined With 4-Aminopyridine and Intensive Rehabilitation in SCI
Spinal Cord Injuries
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury
Chronic Spinal Cord Injury
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ghazal Ebrat contact
Marios C Papadopoulos principal investigator
St George's, University of London, U.K.
Samira Saadoun principal investigator
St George's, University of London, U.K.
34 sites in 12 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Duroplasty and Spinal surgery in people with Spinal Cord Injuries, run by St George's, University of London at 34 sites in 12 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 34 sites in United Kingdom, Austria, Germany, Israel, Belgium and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sophie Reynolds (079 17100953, discus@nds.ox.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in AIS motor score (time frame: 6 months versus baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04936620, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Jul 2026.